ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$25.43
0.34 (1.36%)
▲
5d:
-0.24%
30d:
+17.62%
90d:
+15.12%
BUY
MODERATE Confidence
Analysis Updated: Jul 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
13d
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACAD shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
💡 BUY OPPORTUNITY: ACAD shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.37
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.93
5.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $25.43, which is considered slightly high relative to its 30-day fair value range of $22.56 to $26.25. The stock's valuation (Forward PE: 28.5) is in line with its historical norms (27.3). At these levels, the market is pricing in 1.5% annual earnings growth.
Technical Outlook: Technically, ACAD is in a uptrend. The price is currently testing key support at $24.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.65 (+28.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACAD is in a uptrend. The price is currently testing key support at $24.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.65 (+28.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$22.56 -
$26.25
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.4% below Wall St target ($32.65)
- BULLISH: Expecting earnings turnaround to 1.5% growth with 9.7% revenue growth
Trading Range Analysis
30-Day Trading Range
$22.56 -
$26.25
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$24.95
Resistance Level
$26.51
Current Trend
Uptrend
Technical data as of
Jul 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.54
Wall Street Target
$32.65
(+28.4%)
Revenue Growth (YoY)
9.7%
Earnings Growth (YoY)
-81.8%
Profit Margin
34.3%
Valuation Premium vs History
+1.5% premium
PE vs Historical
28.5 vs 27.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$25.81
(+2%)
2-Year Target
$26.20
(+3%)
3-Year Target
$26.59
(+5%)
3-Yr Target (if PE normalizes)
(PE: 29→27)
PE COMPRESSION
$25.43
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.5, Growth: 133.6%)
$85.83
(+238%)
Base:
(SPY PE: 20.9, Growth: 133.6%)
$62.99
(+148%)
Bear:
(PE: 17.8, Growth: 133.6%)
$53.54
(+111%)
📈
Valuation based on Current Earnings
Trailing PE: 11.58 | Current EPS (TTM): $2.21
Bull Case
$14.08
(-44%)
Analyst growth -50.0%, PE expands to 12.7
Base Case
$12.80
(-49%)
Market implied -50.0%, PE stable at 11.6
Bear Case
$17.41
(-31%)
Severe decline -20.0%, PE contracts to 9.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 21, 2026 5:49 PM ET
Data refreshes hourly during market hours. Next update: 6:49 PM
Data refreshes hourly during market hours. Next update: 6:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$86 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$280 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 55 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
